What is the price of Cemiplimab and its influencing factors?

Cemiplimab (Cemiplimab) is a new type of immune checkpoint inhibitor that mainly activates the patient's own immune system by blocking the PD-1 pathway, thereby identifying and eliminating tumor cells. As an anti-cancer drug that has attracted much attention in recent years, it has been launched in the US and European markets and is used to treat cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), non-small cell lung cancer and other malignant tumors. However, in the Chinese market, the drug has not yet been officially launched and has not been included in medical insurance. Therefore, there is currently no clear data on price in the country.

Judging from overseas market conditions, the price of cimipilimab is relatively expensive. According to public channels, the specification of the original drug in the United States and Europe is 350mg/7mL (50mg/mL), and the price per box is approximately RMB 40,000 to RMB 100,000. The specific cost will change due to exchange rate fluctuations and sales channels. The high price is closely related to its long drug development cycle, high clinical trial costs, and the cutting-edge nature of immunotherapy itself. Compared with some traditional targeted drugs, immune checkpoint inhibitors are usually more expensive in the early stages of marketing due to their difficulty in development and market exclusivity.

Currently, there are no generic drugs of cimepilimab on the market. The main reason is that the drug is still in the patent protection period, and its R&D and production technology requirements are relatively high, so generic drug companies have not yet been able to enter the market. Therefore, if patients want to obtain the drug, they can only purchase it through overseas channels or participate in relevant international clinical research projects. As more competing drugs become available in the future, or as generic drugs are launched after patent expiration, the price of cimepilimab may gradually decrease. Generally speaking, the current high price of this drug is mainly affected by factors such as R&D investment, patent protection, market exclusivity and international exchange rates.

Reference materials:https://www.libtayohcp.com/